SCNX (Scienture Holdings) Cyclically Adjusted Revenue per Share: $14.94 (As of Mar. 2026)


SCNX Scienture Holdings Inc SCNX
47 GF Score
Price $0.35
GF Value $0.35
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Scienture Holdings Cyclically Adjusted Revenue per Share?

Scienture Holdings SCNX 47 Cyclically Adjusted Revenue per Share is $14.94 as of Mar. 2026. GuruFocus rates SCNX with a GF Score™ of 47/100 and a GF Value™ of $0.35 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Scienture Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $14.94 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Scienture Holdings's average Cyclically Adjusted Revenue Growth Rate was -1.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -32.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -26.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Scienture Holdings was -1.50% per year. The lowest was -32.50% per year. And the median was -32.15% per year.

As of today (2026-07-07), Scienture Holdings's current stock price is $0.3455. Scienture Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $14.94. Scienture Holdings's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Scienture Holdings was 2.67. The lowest was 0.02. And the median was 0.50.


Scienture Holdings  (NAS:SCNX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Scienture Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.3455/14.94
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Scienture Holdings was 2.67. The lowest was 0.02. And the median was 0.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Scienture Holdings Cyclically Adjusted Revenue per Share Related Terms


Scienture Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Scienture Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scienture Holdings Cyclically Adjusted Revenue per Share Chart

Scienture Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.53 48.36 15.08 15.30 14.92

Scienture Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.23 0.00 14.72 14.92 14.94

SCNX vs WGRX, HEWA, BLMH: Cyclically Adjusted Revenue per Share Comparison

For the Pharmaceutical Retailers subindustry, Scienture Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scienture Holdings Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Scienture Holdings's Cyclically Adjusted PS Ratio falls into.


SCNX
47GF Score
Scienture Holdings Inc SCNX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scienture Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Scienture Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.001/330.2130*330.2130
=0.001

Current CPI (Mar. 2026) = 330.2130.

Scienture Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.680 241.018 2.302
201609 1.741 241.428 2.381
201612 1.813 241.432 2.480
201703 1.958 243.801 2.652
201706 1.986 244.955 2.677
201709 1.942 246.819 2.598
201712 2.084 246.524 2.791
201803 2.257 249.554 2.986
201806 2.188 251.989 2.867
201809 2.194 252.439 2.870
201812 3.268 251.233 4.295
201903 3.783 254.202 4.914
201906 4.743 256.143 6.115
201909 5.734 256.759 7.374
201912 3.899 256.974 5.010
202003 4.451 258.115 5.694
202006 13.055 257.797 16.722
202009 11.770 260.280 14.932
202012 3.693 260.474 4.682
202103 5.654 264.877 7.049
202106 3.508 271.696 4.264
202109 4.688 274.310 5.643
202112 4.390 278.802 5.200
202203 5.945 287.504 6.828
202206 6.017 296.311 6.705
202209 3.725 296.808 4.144
202212 3.633 296.797 4.042
202303 0.735 301.836 0.804
202306 0.539 305.109 0.583
202309 0.166 307.789 0.178
202312 0.049 306.746 0.053
202403 0.000 312.332 0.000
202406 0.014 314.175 0.015
202409 0.027 315.301 0.028
202412 0.006 315.605 0.006
202503 0.001 319.799 0.001
202506 0.000 322.561 0.000
202509 0.031 324.800 0.032
202512 -0.009 324.054 -0.009
202603 0.001 330.213 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $14.94 mean?
Scienture Holdings (SCNX) has a Cyclically Adjusted Revenue per Share of $14.94 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scienture Holdings and its competitors.
Is Scienture Holdings' Cyclically Adjusted Revenue per Share too high?
Scienture Holdings' current Cyclically Adjusted Revenue per Share is $14.94. Overall, Scienture Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Cyclically Adjusted Revenue per Share compare to WGRX and HEWA?
Scienture Holdings' Cyclically Adjusted Revenue per Share of $14.94 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scienture Holdings and its competitors. Scienture Holdings's current Cyclically Adjusted Revenue per Share is $14.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Fairly Valued. The stock's GF Value™ is $0.35, compared to a current price of $0.35 — trading 1.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $14.94. Scienture Holdings' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Cyclically Adjusted Revenue per Share is $14.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scienture Holdings (SCNX) Overvalued in 2026?

Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued. The current stock price of $0.35 is trading 1.3% below its estimated GF Value™ of $0.35. GuruFocus considers Scienture Holdings to be Fairly Valued.

Key valuation signals for SCNX:

  • Cyclically Adjusted Revenue per Share: $14.94
  • GF Value™: $0.35 vs. price of $0.35 (1.3% below fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scienture Holdings Business Description

Other Exchanges 4E4:Germany
Address 20 Austin Boulevard, Commack, NY, USA, 11725
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score

Get the complete analysis for SCNX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price
$0.35
GF Value